Understanding Cancer from a Systems Biology Point of View From Observation to Theory and Back
Auteur : Kareva Irina
Understanding Cancer from a Systems Biology Point of View: From Observation to Theory and Back starts with a basic question, why do we sometimes observe accelerated metastatic growth after resection of primary tumors? Next, it helps readers understand the systemic nature of cancer and how it affects treatment approaches and decisions. The book puts together aspects of cancer that many readers have most likely never combined, using unfamiliar, novel methods. It is a valuable resource for cancer researchers, cancer biologists, mathematicians and members of the biomedical field who are interested in applying systems biology methodologies for understanding and treating cancer.
1. Introduction2. Tumor dormancy3. Cancer immunoediting: a process driven by metabolic competition as a predator-prey-shared resource type model4. Escape from tumor dormancy and time to angiogenic switch as mitigated by tumor- induced stimulation of stroma5. Angiogenesis regulators as a possible key to accelerated growth of secondary tumors following primary tumor resection6. A combination of immune checkpoint inhibition with metronomic chemotherapy as a way of targeting therapy-resistant cancer cells7. Summary and conclusions
- Explains the systemic nature of cancer and how it affects decisions on treatment
- Brings a variety of methods together, showing, in detail, the logical approach to finding answers to complex questions
- Discusses the theoretical underpinnings of cancer as a systemic disease, providing the reader with valuable information on applicable cases
Date de parution : 02-2018
Ouvrage de 118 p.
15x22.8 cm
Thèmes d’Understanding Cancer from a Systems Biology Point of View :
Mots-clés :
Angiogenesis regulators; Angiogenesis; Angiogenic switch; Chemotherapy; Dormancy; Ecology; Evolution; Fitness; Immunotherapy; Mathematical model; Metastases; Parameter distribution; Population heterogeneity; Primary tumor; Stroma; Surgery; Therapeutic resistance; Tumor dormancy; Tumor microenvironment; VEGF